RecruitingPhase 2NCT06815471
CRF2 Agonist for the Treatment of Worsening Heart Failure
Corticotrophin Releasing Factor 2 for the Treatment of Worsening Heart Failure (WHF) - The CRAFT-WHF Study
Sponsor
Corteria Pharmaceuticals
Enrollment
300 participants
Start Date
Aug 7, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Plain Language Summary
Simplified for easier understanding
This study is testing a new drug that targets a receptor called CRF2 in patients hospitalized for worsening heart failure — a condition where the heart cannot pump enough blood, causing fluid buildup in the body. The drug aims to improve the body's response to diuretics (water pills used to remove excess fluid) in patients who are becoming resistant to standard treatment.
**You may be eligible if...**
- You have been hospitalized for heart failure in the past 12 months
- You are being treated with intravenous (IV) diuretics for fluid overload
- Your heart failure biomarker levels (NT-proBNP or BNP) are significantly elevated
- You have been on oral diuretics for at least one month before this hospitalization
**You may NOT be eligible if...**
- Your hospitalization was primarily caused by a heart attack, blood clot in the lung, or severe irregular heartbeat
- You need IV inotropes, mechanical heart support, or a ventilator
- You have had a solid organ transplant or are on a transplant waiting list
- Your blood pressure is dangerously low (below 100 mmHg)
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCOR-1167
28-day treatment
DRUGPlacebo
28-day treatment
Locations(55)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06815471